Compass Therapeutics (CMPX) Net Equity Issued and Repurchased (2020 - 2025)

Compass Therapeutics (CMPX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $138.0 million in Q3 2025.

• For the quarter ending Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $138.0 million; the trailing twelve-month figure through Dec 2025 stood at $138.0 million (up 661.88% YoY), and the FY2025 full-year result was $138.0 million, up 661.88% from the prior year.
• Net Equity Issued and Repurchased improved to $138.0 million in Q3 2025, from $13000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $138.0 million in Q3 2025 to a low of $13000.0 in Q2 2024.
• A 5-year average of $51.9 million and a median of $18.1 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased slumped 40.44% in 2022 and tumbled 99.58% in 2024, its largest moves.
• Tracing CMPX's Net Equity Issued and Repurchased over 5 years: stood at $128.0 million in 2021, then tumbled by 40.44% to $76.2 million in 2022, then sank by 99.97% to $26000.0 in 2023, then tumbled by 50.0% to $13000.0 in 2024, then surged by 1061430.77% to $138.0 million in 2025.
• Business Quant data shows CMPX's Net Equity Issued and Repurchased at $138.0 million in Q3 2025, $13000.0 in Q2 2024, and $18.1 million in Q1 2024.